Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/17149
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML. |
Author: | White, D. Saunders, V. Lyons, A. Branford, S. Grigg, A. To, L. Hughes, T. |
Citation: | Blood, 2005; 106(7):2520-2526 |
Publisher: | Amer Soc Hematology |
Issue Date: | 2005 |
ISSN: | 0006-4971 0006-4971 |
Statement of Responsibility: | Deborah White, Verity Saunders, A. Bruce Lyons, Susan Branford, Andrew Grigg, L. Bik To, and Timothy Hughes |
Abstract: | Most patients with de novo chronic myeloid leukemia (CML) achieve good responses to imatinib, but the rate and degree of molecular response is variable. We assessed the inhibitory concentration 50% for imatinib (IC50imatinib) in 62 patients with de novo chronic-phase CML as a predictor of molecular response. IC50imatinib was determined in pretherapy blood samples by measuring the in vitro imatinib-induced reduction of the phosphorylated form of the adaptor protein Crkl (CT10 regulator of kinase like). There was marked variability between patients, with IC50imatinib ranging from 0.375 to 1.8 microM (median, 0.6 microM). Patients with low IC50imatinib (IC50 < or = 0.6 microM; n = 36) had a 36% probability of achieving 2-log reduction in BCR-ABL (breakpoint cluster region-abelson) by 3 months compared with 8% in patients with high IC50imatinib (n = 26) (P = .01). The IC50imatinib was also predictive of molecular response at 12 months, with 47% of patients in the low IC50imatinib group achieving 3-log reduction and 23% in the high IC50imatinib group (P = .03). The predictive power of IC50imatinib was particularly strong in patients with low Sokal scores. These data provide strong evidence that intrinsic sensitivity to imatinib is variable in previously untreated patients with CML, and the actual level of BCR-ABL kinase inhibition achieved is critical to imatinib response. The IC50imatinib potentially provides a new prognostic indicator for molecular response in patients treated with imatinib. |
Keywords: | K562 Cells Chromosomes, Human, Pair 9 Humans Benzamides Piperazines Pyrimidines Proto-Oncogene Proteins c-abl Adaptor Proteins, Signal Transducing Fusion Proteins, bcr-abl Oncogene Proteins Nuclear Proteins Antineoplastic Agents Protein Kinase Inhibitors Blotting, Western Prognosis Treatment Outcome Drug Screening Assays, Antitumor Inhibitory Concentration 50 Cell Proliferation Phosphorylation Dose-Response Relationship, Drug Genes, abl Time Factors Leukemia, Myelogenous, Chronic, BCR-ABL Positive In Vitro Techniques Imatinib Mesylate |
DOI: | 10.1182/blood-2005-03-1103 |
Published version: | http://dx.doi.org/10.1182/blood-2005-03-1103 |
Appears in Collections: | Aurora harvest 6 Pathology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.